Soft Tissue Infection Clinical Trial
Official title:
Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections
To examine the effect of Point-of-Care Ultrasound (POCUS) management guidance on pediatric skin and soft tissue infections treatment failure rate, as well as emergency department process outcome.
Status | Completed |
Enrollment | 280 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 19 Years |
Eligibility |
Inclusion Criteria: - history and examination findings consistent with possible abscess or cellulitis per the treating clinician. - minimal lesion diameter for inclusion is 1cm. Exclusion Criteria: - suspected soft tissue infections involving or near mucosal membranes (e.g. perirectal, peritonsillar, vulvovaginal areas) - facial lesions - paronychia or felon - parent or patient refusal of consent - unsuitable subjects deemed by treating clinicians. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Advocate Christ Medical Center | Oak Lawn | Illinois |
Lead Sponsor | Collaborator |
---|---|
May Alrahi | American College of Emergency Physicians, Children's Hospital & Research Center Oakland, Maimonides Medical Center, Montefiore Medical Center, Newark Beth Israel Medical Center, Texas Children's Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | treatment failure rate | unscheduled return visits need for subsequent procedural intervention need for subsequent admission change in therapy | 7-10days | No |
Secondary | emergency department process outcome | emergency department (ED) length of stay, need for ED procedural sedation use of alternative imaging in ED | 7-10days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00658866 -
Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection
|
Phase 4 |